Autologous CAR-T cells directed against the pan-B-cell antigen CD19 have been approved for acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), after showing high remission rates in heavily pretreated patients, which in some may be durable (2, 3). Here, CD19 is linked to acute lymphoblastic leukemia.